ClinicalTrials.gg
RecruitingNCT07517523ADVERSE-MIUpdated May 28, 2026

Ventricular Arrhythmias in Acute Myocardial Infarction

An observational study in Ventricular Arrhythmia and Acute Myocardial Infarction (AMI), sponsored by Poitiers University Hospital. Recruiting at 8 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Poitiers University Hospital · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in ST Elevation Myocardial Infarction with a site in France — 7 open to participants now, 11 under way, 5 of them phase 3. ST Elevation Myocardial Infarction · France.

Started
2025
with 1 other
Observational
9 of 49
2 open now
Primary completion
2026-10
later than 3 of 10 live
Registered
49th of 49
by date

Among the 49 studies in ST Elevation Myocardial Infarction with a site in France, this one is one of 2 that started in 2025, is one of 9 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 49th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

7 of the 49 studies in ST Elevation Myocardial Infarction with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in ST Elevation Myocardial Infarction with a site in France, or all of them as a file.
02

Study summary

Ventricular arrhythmias are a serious complication of myocardial infarction. The aim of this study is to provide reliable data on the management and mortality associated with ventricular arrhythmia in the setting of acute myocardial infarction.

Read the detailed description

Ventricular arrhythmias remain a major complication during the acute phase of myocardial infarction. The 2022 European guidelines on ventricular arrhythmias recommend implantable cardioverter-defibrillator (ICD) placement for secondary prevention when ventricular fibrillation occurs ≥ 48 hours after the infarct. Yet this recommendation rests on limited evidence. We therefore conduct a multicentre retrospective study to characterise the clinical profile, management, and prognosis of sustained ventricular arrhythmias (ventricular tachycardia and ventricular fibrillation) arising in the acute myocardial infarction setting.

The primary objective of this study is to evaluate post-discharge mortality in patients who develop an arrhythmia either within 48 hours of, or more than 48 hours after, an acute myocardial infarction. Sensitivity analyses will further examine outcomes according to the arrhythmia subtype (ventricular fibrillation vs ventricular tachycardia), the presence of concomitant heart failure, and the myocardial-infarction phenotype (STEMI vs NSTEMI).

03

Conditions studied

  • Ventricular Arrhythmia
  • Acute Myocardial Infarction (AMI)

Keywords

  • ST-segment elevation myocardial infarction
  • non-ST-segment elevation myocardial infarction
  • ventricular fibrillation
  • ventricular tachycardia
  • cardiac arrest
  • implantable cardioverter defibrillator
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All included individuals will be consecutive patients who developed a sustained ventricular arrhythmia during the acute phase of a myocardial infarction between January 1, 2012, and April 14, 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years
  • Acute myocardial infarction
  • Sustained ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) at the acute phase of an acute myocardial infarction (before hospital discharge)
  • Between January 1, 2012 and April 14, 2024

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ventricular arrhythmia

    patients who developed a sustained ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) during the acute phase of myocardial infarction, i.e., from infarct onset to hospital discharge

06

What researchers measure

Primary outcomes

  1. Post-discharge mortality

    Time frame: through study completion, an average of 2 years

Secondary outcomes

  1. Baseline demographic and clinical characteristics at inclusion

    This outcome is the characterization of the study population at baseline, including demographic, and clinical-related variables collected at the time of myocardial infarction.

    Time frame: At baseline

  2. Number of participants fot each type of myocardial infarction

    Includes revascularization strategy and other therapeutic management measures implemented during the index hospitalization.

    Time frame: At baseline

  3. Number of participants with each ventricular arrhythmia characteristic and management strategy during index hospitalization

    Descriptive summary of ventricular arrhythmia presentation and in-hospital management, including arrhythmia type, timing of occurrence, recurrence, and therapeutic interventions.

    Time frame: At baseline

  4. In-hospital mortality

    proportion of patients who die during their hospital stay, before discharge

    Time frame: From admission until the date of death or hospital discharge, whichever came first, assessed up to 28 days

  5. Number of participants with wearable cardioverter-defibrillator utilization

    Time frame: At baseline

  6. Rate of recurrent myocardial infarction after hospital discharge

    Time frame: through study completion, an average of 2 years

  7. Rate of recurrent ventricular arrhythmias after hospital discharge

    Time frame: through study completion, an average of 2 years

  8. Rate of defibrillator implantation during hospitalization and after hospital discharge

    Time frame: through study completion, an average of 2 years

  9. Number of participants, incidence, characteristics, and management of electrical storms

    Time frame: At baseline

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2026
First posted
Apr 8, 2026
StartActual
Jun 20, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2027
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07517523
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Jun 20, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
May 28, 2026

Study contacts

Véronique Le Marcis
Contact
veronique.le-marcis@chu-poitiers.fr
+33 5 49444084
Rodrigue Garcia, MD; PhD
principal investigator · Cardiology department and CIC 1402; University Hospital of Poitiers

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion